RA Capital Management 13F holdings, Q3 2016
Holdings as of September 30, 2016 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 30 US equity positions worth $969.4m in its Q3 2016 13F filing. The largest position was WVE at 23.7% of the reported book, followed by ACHILLION PHARMACEUTICALS INC and ASND. Against the Q2 2016 filing, it opened 5 new positions, added to 8 and reduced 7 among the top 30 holdings.
What did RA Capital Management own in Q3 2016? Top 30 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q2 2016 |
|---|---|---|---|---|---|---|---|
| 1 | WVE WAVE LIFE SCIENCES PTE LTD | Healthcare | 23.7% | $230.2m | 7,088,651 | 0% | held |
| 2 | ACHILLION PHARMACEUTICALS INC | 10.1% | $97.5m | 12,033,220 | 0% | held | |
| 3 | ASND ASCENDIS PHARMA A S | Healthcare | 7.6% | $74.0m | 3,681,491 | 8% | added |
| 4 | AVEXIS INC | 7.4% | $71.4m | 1,732,274 | 29% | added | |
| 5 | AXOVANT SCIENCES LTD | 7.2% | $70.0m | 5,000,000 | 0% | held | |
| 6 | NKTR NEKTAR THERAPEUTICS | Healthcare | 6.5% | $63.0m | 3,664,154 | 14% | added |
| 7 | ARDX ARDELYX INC | Healthcare | 4.4% | $42.3m | 3,266,045 | 41% | added |
| 8 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 4.1% | $39.6m | 1,547,152 | -41% | reduced |
| 9 | TGTX TG THERAPEUTICS INC | Healthcare | 3.7% | $35.8m | 4,631,114 | 2% | added |
| 10 | MERUS N V | 3.2% | $31.5m | 2,656,166 | 8% | added | |
| 11 | AQUINOX PHARMACEUTICALS INC | 3.0% | $29.3m | 2,191,977 | 30% | added | |
| 12 | AIMT AIMMUNE THERAPEUTICS INC | 2.0% | $19.4m | 1,292,940 | 0% | held | |
| 13 | FOAMIX PHARMACEUTICALS LTD | 1.7% | $16.9m | 1,820,138 | – | new | |
| 14 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 1.6% | $15.9m | 754,411 | – | new |
| 15 | PROTEON THERAPEUTICS INC | 1.6% | $15.2m | 1,626,931 | 0% | held | |
| 16 | DICERNA PHARMACEUTICALS INC | 1.5% | $14.3m | 2,428,571 | 0% | held | |
| 17 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 1.4% | $13.2m | 2,989,795 | 0% | held |
| 18 | STRONGBRIDGE BIOPHARMA PLC | 1.3% | $13.1m | 2,501,667 | -6% | reduced | |
| 19 | AUDENTES THERAPEUTICS INC | 1.3% | $12.6m | 707,426 | – | new | |
| 20 | DIMENSION THERAPEUTICS INC | 1.3% | $12.4m | 1,548,033 | 0% | held | |
| 21 | XLRN ACCELERON PHARMA INC | 1.2% | $11.5m | 318,565 | – | new | |
| 22 | ARWR ARROWHEAD PHARMACEUTICALS INC | Healthcare | 1.2% | $11.2m | 1,525,424 | – | new |
| 23 | TENX TENAX THERAPEUTICS INC | 0.6% | $5.5m | 2,389,700 | 0% | held | |
| 24 | ONC BEIGENE LTD | Healthcare | 0.5% | $5.2m | 170,000 | 0% | held |
| 25 | ALCOBRA LTD | 0.5% | $5.1m | 2,044,756 | -33% | reduced | |
| 26 | EIGER BIOPHARMACEUTICALS INC | 0.5% | $4.7m | 354,200 | 21% | added | |
| 27 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 0.4% | $4.2m | 899,438 | -23% | reduced |
| 28 | AEGLEA BIOTHERAPEUTICS INC | 0.2% | $2.2m | 336,134 | -36% | reduced | |
| 29 | ARCA BIOPHARMA INC | 0.2% | $1.5m | 521,606 | -7% | reduced | |
| 30 | AKTX AKARI THERAPEUTICS PLC | 0.1% | $970.0k | 114,039 | -51% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.